Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population
Klotho Neurosciences (NASDAQ: KLTO) has announced a partnership with the Okinawa Research Center for Longevity Science (ORCLS) to study tissue levels of the human Klotho gene and protein in Okinawa's centenarian population. The research focuses on understanding how the alpha-Klotho protein may contribute to healthy longevity and lifespan.
The collaboration will analyze blood samples from ORCLS's extensive centenarian study database to investigate the role of Klotho protein in promoting longevity and reducing risks of neurodegenerative diseases. KLTO's preliminary data suggests that maintaining optimum blood levels of Klotho protein in later life correlates with longevity, while lower levels are associated with premature aging and neurological disorders.
The company's patent-protected secreted s-KL protein isoform shows promise for treating conditions like ALS, Alzheimer's, Parkinson's, and other age-related disorders including sarcopenia, osteoporosis, diabetes, and cardiovascular conditions.
Klotho Neurosciences (NASDAQ: KLTO) ha annunciato una collaborazione con il Centro di Ricerca per la Scienza della Longevità di Okinawa (ORCLS) per studiare i livelli tissutali del gene e della proteina Klotho umana nella popolazione centenaria di Okinawa. La ricerca si concentra sul comprendere come la proteina alfa-Klotho possa contribuire a una longevità sana e alla durata della vita.
La collaborazione analizzerà campioni di sangue provenienti dall'ampio database dello studio centenario di ORCLS per indagare il ruolo della proteina Klotho nel promuovere la longevità e nel ridurre i rischi di malattie neurodegenerative. I dati preliminari di KLTO suggeriscono che mantenere livelli ottimali di proteina Klotho nel sangue nelle fasi avanzate della vita è correlato alla longevità, mentre livelli più bassi sono associati a un invecchiamento precoce e a disturbi neurologici.
L'isoforma proteica secreta s-KL, protetta da brevetto, mostra potenzialità per il trattamento di condizioni come ALS, Alzheimer, Parkinson e altre patologie legate all'età, tra cui sarcopenia, osteoporosi, diabete e malattie cardiovascolari.
Klotho Neurosciences (NASDAQ: KLTO) ha anunciado una asociación con el Centro de Investigación de Ciencia de la Longevidad de Okinawa (ORCLS) para estudiar los niveles tisulares del gen y la proteína humana Klotho en la población centenaria de Okinawa. La investigación se centra en comprender cómo la proteína alfa-Klotho puede contribuir a una longevidad saludable y a la extensión de la vida.
La colaboración analizará muestras de sangre del extenso banco de datos del estudio centenario de ORCLS para investigar el papel de la proteína Klotho en la promoción de la longevidad y la reducción del riesgo de enfermedades neurodegenerativas. Los datos preliminares de KLTO sugieren que mantener niveles óptimos de proteína Klotho en sangre en la vejez se correlaciona con la longevidad, mientras que niveles bajos están asociados con envejecimiento prematuro y trastornos neurológicos.
La isoforma de proteína secretada s-KL protegida por patente de la compañía muestra potencial para tratar condiciones como ELA, Alzheimer, Parkinson y otros trastornos relacionados con la edad, incluyendo sarcopenia, osteoporosis, diabetes y enfermedades cardiovasculares.
Klotho Neurosciences (NASDAQ: KLTO)는 오키나와 장수 과학 연구 센터(ORCLS)와 협력하여 오키나와의 백세인 인구에서 인간 Klotho 유전자와 단백질의 조직 내 수준을 연구한다고 발표했습니다. 이 연구는 알파-Klotho 단백질이 건강한 장수와 수명에 어떻게 기여하는지 이해하는 데 중점을 둡니다.
이번 협력은 ORCLS의 광범위한 백세인 연구 데이터베이스에서 혈액 샘플을 분석하여 Klotho 단백질이 장수를 촉진하고 신경퇴행성 질환의 위험을 줄이는 역할을 조사할 예정입니다. KLTO의 예비 데이터에 따르면, 노년기에 혈중 Klotho 단백질의 최적 수준을 유지하는 것이 장수와 연관되며, 낮은 수준은 조기 노화와 신경학적 장애와 관련이 있습니다.
회사의 특허 보호를 받는 분비형 s-KL 단백질 아이소폼은 ALS, 알츠하이머, 파킨슨병 및 근감소증, 골다공증, 당뇨병, 심혈관 질환 등 연령 관련 질환 치료에 유망한 가능성을 보이고 있습니다.
Klotho Neurosciences (NASDAQ: KLTO) a annoncé un partenariat avec le Centre de Recherche pour la Science de la Longévité d'Okinawa (ORCLS) afin d'étudier les niveaux tissulaires du gène et de la protéine Klotho humaine chez la population centenaire d'Okinawa. La recherche vise à comprendre comment la protéine alpha-Klotho pourrait contribuer à une longévité saine et à la durée de vie.
Cette collaboration analysera des échantillons sanguins issus de la vaste base de données de l'étude centenaire d'ORCLS pour examiner le rôle de la protéine Klotho dans la promotion de la longévité et la réduction des risques de maladies neurodégénératives. Les données préliminaires de KLTO suggèrent que le maintien de niveaux optimaux de protéine Klotho dans le sang en fin de vie est corrélé à la longévité, tandis que des niveaux plus faibles sont associés à un vieillissement prématuré et à des troubles neurologiques.
L'isoforme protéique sécrétée s-KL, protégée par brevet, montre un potentiel prometteur pour le traitement de maladies telles que la SLA, Alzheimer, Parkinson et d'autres troubles liés à l'âge, notamment la sarcopénie, l'ostéoporose, le diabète et les maladies cardiovasculaires.
Klotho Neurosciences (NASDAQ: KLTO) hat eine Partnerschaft mit dem Okinawa Research Center for Longevity Science (ORCLS) bekannt gegeben, um die Gewebelevel des menschlichen Klotho-Gens und -Proteins in der centenarian Bevölkerung von Okinawa zu untersuchen. Die Forschung konzentriert sich darauf, zu verstehen, wie das Alpha-Klotho-Protein zu gesunder Langlebigkeit und Lebensdauer beitragen kann.
Die Zusammenarbeit wird Blutproben aus der umfangreichen Centenarian-Studien-Datenbank von ORCLS analysieren, um die Rolle des Klotho-Proteins bei der Förderung der Langlebigkeit und der Verringerung des Risikos neurodegenerativer Erkrankungen zu untersuchen. Vorläufige Daten von KLTO deuten darauf hin, dass das Aufrechterhalten optimaler Blutspiegel des Klotho-Proteins im späteren Leben mit Langlebigkeit korreliert, während niedrigere Werte mit vorzeitigem Altern und neurologischen Störungen verbunden sind.
Die patentgeschützte sekretierte s-KL-Protein-Isoform des Unternehmens zeigt vielversprechende Ansätze zur Behandlung von Erkrankungen wie ALS, Alzheimer, Parkinson und anderen altersbedingten Störungen, einschließlich Sarkopenie, Osteoporose, Diabetes und Herz-Kreislauf-Erkrankungen.
- Preliminary data suggests Klotho protein's potential role in healthy longevity
- Partnership with world's largest ongoing centenarian study
- Access to extensive biological samples and clinical data from ORCLS
- Patent protection for secreted s-KL protein isoform
- Promising animal study results in treating degenerative neurological conditions
- Animal study results may not translate to human clinical success
- Klotho blood and tissue levels naturally decrease with age
Insights
KLTO partners with Okinawa longevity researchers to study how Klotho protein levels correlate with exceptional lifespan and neurological health.
Klotho Neurosciences has formed a strategic research partnership with the Okinawa Research Center for Longevity Science to investigate the role of the Klotho protein in human longevity. This collaboration targets a compelling scientific question: why do Okinawans live exceptionally long, healthy lives, and could the Klotho protein be a key factor?
The significance of this research stems from preliminary data suggesting the human alpha-Klotho gene and its secreted protein isoform (s-KL) may contribute to healthy longevity. As humans age, α-Klotho levels decrease in blood and tissues, preceding various age-related pathologies. The most intriguing aspect is that replenishing s-KL via gene therapy potentially protects against neurodegenerative disorders like ALS, Alzheimer's, and Parkinson's, alongside other age-related conditions affecting muscles, bones, heart, liver, and kidneys.
KLTO brings a patent-protected secreted s-KL protein isoform to this collaboration, which demonstrated "exceptional results" in animal studies. While animal results don't always translate to humans, this partnership provides access to the world's largest ongoing study of centenarians and decades of biological samples. The first phase will analyze centenarian blood samples to establish Klotho protein's role in promoting longevity and reducing neurodegenerative disease risks.
This research has broad implications beyond neurology, potentially impacting treatment approaches for sarcopenia, osteoporosis, diabetes, and cardiovascular disorders – all major markets with significant unmet medical needs. The partnership leverages ORCLS's half-century of groundbreaking longevity research, including discovering the first human longevity genes and validating longevity gene findings from animal models in humans.
Commenting on this significant opportunity, Dr. Joseph Sinkule, the CEO of KLTO, noted that "animal studies using the Klotho gene in degenerative neurological conditions produced extremely interesting results. KLTO and ORCLS scientists believe the maintenance of optimum blood levels of the Klotho protein in later life correlates with longevity, whereas lower blood levels are associated with premature aging and a propensity to develop certain neurological disorders. While results in animal studies do not always translate into success in human clinical studies, we were very encouraged by the exceptional results, and believe that our patent protected secreted s-KL protein isoform of the Klotho gene holds real promise for the development of effective treatments for neurological disorders, as well as other age-related disorders such as sarcopenia, osteoporosis, diabetes and various renal and cardiovascular disorders. We are confident that our work with the highly experienced team of medical researchers and other well-known scientists at the ORCLS will provide groundbreaking evidence that the Klotho protein levels in humans are one of several highly critical factors for sustaining human health span, including avoidance of neurological and other age-related disorders."
Dr. Bradley Willcox, MD, MSc, FGSA, FRSM, a leading member of the Okinawa Research Center for Longevity Science, stated that "for the last 50 years, our ORCLS Team, led by Dr. Makoto Suzuki, has been producing groundbreaking research on human aging and longevity. ORCLS scientists created the world's largest, ongoing study of centenarians in the world, discovered the first human longevity genes (Lancet, 1987), and were the first to validate and translate longevity gene findings in mice and other model organisms to humans (PNAS 2008), among other notable discoveries in aging. We have collected and banked biological samples and clinical data, including blood and tissue samples over many years. A selection of these centenarian blood samples will be analyzed in the first phase of our research partnership with KLTO, where we will assess blood levels of the Klotho protein to establish the role of the Klotho protein in promoting longevity and reducing the risks of neurodegenerative diseases, such as ALS, AD and PD, as well as diabetes and cardiovascular disorders."
The Klotho gene was named after the mythologic Greek goddess, Clotho, who was said to "spin the thread of life." The Blue Zones are located in
About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and it's novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
Investor Contact and Corporate Communications –
Jeffrey LeBlanc, CFO
jeff@klothoneuro.com
Website: www.klothoneuro.com.
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the
View original content to download multimedia:https://www.prnewswire.com/news-releases/klotho-neurosciences-inc-and-the-okinawa-research-center-for-longevity-science-leading-experts-on-the-okinawa-blue-zone-announce-a-plan-to-study-tissue-levels-of-the-human-klotho-gene-and-protein-in-the-worlds-longest-lived-302489021.html
SOURCE Klotho Neurosciences, Inc.
FAQ
What is the partnership between Klotho Neurosciences (KLTO) and ORCLS?
What potential treatments is KLTO developing using the Klotho protein?
What are the key findings about Klotho protein levels and aging?
How will ORCLS contribute to KLTO's research?
What are the risks in KLTO's Klotho protein research?
